Novartis | NOVN - Interest Expense On Debt


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Novartis

Novartis reported $211M in Interest Expense on Debt for its fiscal quarter ending in March of 2023.


Interest Expense On Debt Change
Alcon AG ALC:SW USD 47M 7M
Amgen AMGN:US USD 543M 128M
Biogen BIIB:US USD 62.5M 7.7M
Bristol-Myers Squibb BMY:US USD 288M 6M
Eli Lilly LLY:US USD 102.8M 18.8M
Genmab GEN:DC DKK 6M 1000K
Gilead Sciences GILD:US USD 230M 3M
J&J JNJ:US USD 215M 38M
Lonza Group LONN:SW CHF 32M 4M
Novartis NOVN:VX USD 211M 8M
Novartis NVS:US USD 211M 8M
Pfizer PFE:US USD 318M 5M
Recordati REC:IM EUR 14.45M 2.57M
Regeneron Pharmaceuticals REGN:US USD 18M 600K
Roche Holding ROG:VX CHF 348M 92M